secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2022-04-18T23:59:59+00:00
Accession:  0001140361-22-014868
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers to revise non-GAAP reporting; Q1 2022 impact of -$0.10/share from Acquired IPRD
--------------------------------------------------------------------------------

- Starting Q1 2022, non-GAAP results will include significant R&D charges from asset acquisitions and licensing, previously excluded.
- 2021 non-GAAP diluted EPS revised down to $7.16 from $7.51; 2020 GAAP shows new $12.5B Acquired IPRD line.
- Preliminary Q1 2022 estimate: net negative impact of approx. $0.10/share from Acquired IPRD charges and licensing income.
- Change follows SEC discussions; historical financials for 2020-2021 restated for comparability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000114036122014868/0001140361-22-014868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000114036122014868/brhc10036367_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-014868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer